I would prefer the latter. My remarks tended to say that these are the kinds of problems you're going to have if you try to integrate some kind of work-based model like the one in Quebec with the public system, which just picks up the outliers who aren't covered with a workplace plan. You're going to have all those increased costs that workplace plans entail, and you're going to have a lack of general coverage for the population and a lack of capacity to negotiate the prices of drugs with pharmaceutical companies, so you're going to be looking at a much more expensive system with results that are not as good.
On May 16th, 2016. See this statement in context.